FiercePharmaOriginal article
{"a":[{"_":"How 2 FDA citations complicate Hengrui, Elevar’s push for liver cancer combo approval","$":{"href":"/pharma/how-2-fda-citations-complicate-hengrui-elevar-push-liver-cancer-combo-approval","hreflang":"en"}}]}
Negative
AI Analysis
Summary
Hengrui Pharma and Elevar Therapeutics face continued regulatory hurdles in their fourth approval attempt for a liver cancer combination therapy, as a second FDA citation complicates their path forward despite resolving prior manufacturing issues.
Outcome Details
Complete response letter citing manufacturing and other regulatory issues; fourth approval attempt
Importance:6/10
Sentiment:
-0.70
FDACRLliver cancercombination therapymanufacturingregulatory setback
Read the original article
Published by FiercePharma on July 28, 2026 2:42 PM